Ad
related to: gilead sciences
Search results
Gilead, with approval in sight, shows $4.3B liver disease drug improves outcomes out to 2 years
FierceBiotech· 4 hours agoThe molecule, seladelpar, had already moved the needle in a phase 3 trial by the time Gilead paid...
Gilead’s Phase III urothelial cancer trial fails to meet primary endpoint
Clinical Trials Arena via Yahoo Finance· 5 days agoGilead Sciences has reported that its Phase III TROPiCS-04 clinical trial of Trodelvy in patients...
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival
Reuters via AOL· 5 days ago(Reuters) -Gilead Sciences' Trodelvy failed to improve survival for patients with advanced bladder...
Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?
Motley Fool via Yahoo Finance· 2 hours agoKHC Revenue (TTM) data by YCharts. The final stock on this list is biotech giant Gilead Sciences...
...Most Common Type Of Bladder Cancer Why Is Gilead Sciences Stock Trading Lower On Friday? - Gilead...
Benzinga· 5 days agoOn Thursday, Gilead Sciences Inc GILD announced topline results from the confirmatory Phase 3...
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Zacks via Yahoo Finance· 5 days agoGilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or...
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention...
Benzinga· 18 hours agoThe mid-stage studies will assess the safety, acceptability, and pharmacokinetics (how a drug moves...
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
Zacks via Yahoo Finance· 2 days agoGilead Sciences, Inc. GILD and partner Arcus Biosciences, Inc. RCUS announce new data from Cohort B...
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention...
Benzinga via Yahoo Finance· 20 hours agoThe mid-stage studies will assess the safety, acceptability, and pharmacokinetics (how a drug moves...
KYTX Stock Sees Decline of Approximately
Knox Daily· 6 days agoInvestors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Kyverna Therapeutics Inc. shares valued at $20,020,000 were purchased by < ...
